

CURRICULUM VITAE

January 2020

Name: Randall R. Reves, M.D., M.Sc.

Address: 635 Detroit Street
Denver, Colorado 80206

Birthplace and Date: Abilene, Texas; February 20, 1948

Citizenship: U.S.A.

Marital Status: Married, Janet Kay
Children: Brant, Brooke, Amanda, Colby

Undergraduate Education: University of Texas at Austin B.S.,
cum laude, 1970

Graduate Education: University of Texas Medical Branch,
Galveston, M.D., cum laude, 1975

London School of Hygiene and Tropical
Medicine, M.Sc. in Epidemiology, 1983

Postgraduate Training: 1975-1976 - University of Wisconsin
Hospitals, Madison, Department of Medicine, Intern

1976-1977 - University of Wisconsin
Hospitals, Madison, Department of Medicine, Junior
Resident

1977-1979 - Center for Disease Control,
U.S.P.H.S., Field Services Division, Jackson,
Mississippi, Epidemic Intelligence Service Officer

1979-1980 - University of Texas Medical
School at Houston, Department of Internal Medicine,
Senior Resident

1981-1982 - University of Texas Medical School at
Houston, Department of Infectious Diseases and Clinical
Microbiology, Fellow

Academic Appointments:

1980-1981 - University of Texas Medical School at Houston, Department of Internal Medicine, Instructor in Internal Medicine and Chief Resident

1981-1984 - University of Texas Medical School at Houston, Department of Internal Medicine and Program in Infectious Diseases and Clinical Microbiology, Instructor

1983-1984 - St. Mary's Hospital Medical School, London, Academic Department of Community Medicine, Research Fellow in Epidemiology

1984-1989 - University of Texas Medical School at Houston, Department of Medicine and Program in Infectious Diseases and Clinical Microbiology, Assistant Professor

1989-1990 - University of Texas Medical School at Houston, Department of Medicine, Division of General Internal Medicine, Assistant Professor

1984-1990 - University of Texas School of Public Health, Assistant Professor of Epidemiology

1991-2005 - University of Colorado Health Science Center, Department of Medicine, Division of Infectious Diseases, Associate Professor

1991-2005 - University of Colorado Health Science Center, Department of Preventive Medicine and Biometrics, Associate Professor

2005-2008 - University of Colorado Health Science Center, Department of Preventive Medicine and Biometrics, Professor

2005-present - University of Colorado Denver, School of Medicine, Department of Medicine, Division of Infectious Diseases, Professor

2012-present – University of Colorado Denver, School of Public Health, Professor

Hospital Appointments:

1980-1990 - Active Staff in Internal Medicine at Hermann Hospital, Houston, Texas

1985-1989 - Member of the Infection Control Committee, Hermann Hospital, Houston, Texas

1986-1989 - Medical Director of the Epidemiology and Infection Control Department, Hermann Hospital, Houston, Texas

1985-1989 - Member of Pharmacy and Therapeutics Committee at Hermann Hospital (1987-1989, Chairman of the Subcommittee on Antibiotics)

1990-2013 - Active Staff in Internal Medicine at Denver Health, Denver, Colorado

1991-2013 - Member of the Infection Control Committee, Denver Health, Denver, Colorado (Chairman 1991-94)

2014-present - Volunteer in Internal Medicine at Denver Health, Denver, Colorado

Service to the Community:

1986-1990 - Member, Tuberculosis Committee the American Lung Association/San Jacinto Area.

1989-1990 - Member, Medical Advisory Council AIDS Alliance of Houston.

1988-1990 - Consultant, AIDS Education and Training Center for Texas and Oklahoma, University of Texas School of Public Health

1989-1990 - Medical Consultant, Tuberculosis Control Program, Health and Human Services, City of Houston

1990-February 2013 - Director, Denver Metro Tuberculosis Control Program

1990-2000 - Co-director, Denver Metro Infectious Disease Clinic.

1994-95 - Member, Governor's AIDS Council, Colorado

1995 - present - Member, National Tuberculosis Controllers Association.

Member, Executive Committee 1995-97, 2002-04
President-Elect 2002, President 2003, Past-president 2004

2000- present - Member, Colorado Coalition Against Tuberculosis

2001 - Member, Tuberculosis Control Committee for the revision of the CDC/ATS/IDSA recommendations for tuberculosis control. External reviewer for the tuberculosis treatment guidelines.

2004- present – Steering Committee Member, Stop TB USA (formerly the National Coalition for the Elimination of Tuberculosis). Chair 2016-2018

2005-15 Member Board of Directors, Denver Medical Society

Licensure:

30472, Colorado 1990

Certification:

Diplomate, American Board of Internal Medicine, 1980

Professional Organizations:

Member, American College of Physicians
Member, Infectious Diseases Society of America
Member, American Thoracic Society

Member, Colorado Trudeau Society
Member, International Union against Tuberculosis and Lung Diseases, President Elect for the North American Region 2013-2015, President 2015-2017, Past-President 2017-2018

Honors and Awards:

Alpha Omega Alpha, 1975
Scholar of the Milbank Memorial Fund Clinical Epidemiology Program, 1982-87
Best Doctors In America, Central Region 1997
Best Doctors in America, 2004-6, 2007-13
Colorado Thoracic Society Outstanding Clinician of the Year, 2011
William Stead Clinician Award, National Tuberculosis Controllers Association, 2014

REVIEW ACTIVITIES

Journal Articles

American Journal of Public Health
BMC Infectious Diseases
American Journal of Respiratory and Critical Care Medicine, Associate Editor 2008
Annals of Internal Medicine
Annals of the American Thoracic Society
Archives of Internal Medicine Diseases
Clinical Infectious Diseases
Emerging Infectious Diseases
European Respiratory Journal
International Journal of Tuberculosis and Lung Disease
Journal of the American Medical Association
Journal of Immigration and Minority Health
Journal of Infectious Diseases
Lancet Infectious Diseases
Plos One
Public Health Reports

GRANTS AND CONTRACTS AWARDED

1. "Denver Community Program for Clinical Research on AIDS (CPCRA)", P.I., David Cohn, National Institute for Allergy and Infectious Diseases, 1989 – 2005, Staff Physician
2. "Evaluation of Counseling and Testing of TB Patients for HIV Infection and Reporting of Test Results," P.I.-Randall Reves, Centers for Disease Control and Prevention (CDC P.I., Eileen Schneider), 1996-1998
3. "Tuberculin Skin Testing Demonstration - Evaluation of *staffTrak-TB*, Software for Surveillance of Tuberculosis Infection in Health Care Workers", P.I.-Randall Reves, Centers for Disease Control and Prevention (CDC P.I., Lauren Lambert), 1996-1998
4. "Evaluation of Contact Investigations of TB Cases and Prospective Evaluation of Immunogenetic Susceptibility to *Mycobacterium tuberculosis* Infection and Surrogate Markers for Tuberculosis Infection and Disease", P.I.-Randall Reves, Centers for Disease Control and Prevention (CDC P.I., Mary Reichler), 1997-2002
5. "Short-course Treatment of TB Infection in High-risk, Difficult-to-reach Populations," P.I.-Randall Reves, Centers for Disease Control and Prevention (CDC P.I., Mark Lobato), 1999-2001

6. "Tuberculosis Trials Consortium," P.I.-Randall Reves 9/14/04 – 9/28/11, Centers for Disease Control and Prevention, \$4,226,182 total award
7. "Demonstrating and Measuring the Impact of Elimination in Areas of Low Incidence of TB," P.I.-Randall Reves, Centers for Disease Control and Prevention, 2000 – 2003
8. "TB *QuantifERON*," P.I.-Randall Reves, Centers for Disease Control and Prevention (CDC P.I., Jerry Mazurek), 1999-2003
9. "TB Epidemiological Studies Consortium," P.I.-Randall Reves, Centers for Disease Control and Prevention, 2001-2011. Member Research Agenda Committee, 2002-2006, Chair 2002-2006, Co-Chair 2006-present. Member, External Relations Committee, 2003-2011.
10. "Denver Community Program for Clinical Research on AIDS (CPCRA) Funding Agency: National Institute for Allergy and Infectious Diseases. September 30, 1989 – May 31, 2011.
11. Tuberculosis Epidemiologic Studies Consortium #13. CDC. April 30, 2004 – July 31, 2009.
12. Tuberculosis Epidemiologic Studies Consortium #18 – Evaluation of New Interferon Release Assays. Funding Agency: CDC. September 14, 2006 – August 14, 2010.
13. Tuberculosis Epidemiologic Studies Consortium #20 – Evaluation of a gamma interferon release assay compared with tuberculin skin testing in tuberculosis screening of visa applicants in Vietnam. Funding Agency: CDC. 10/01/07– 9/27/2011
14. Tuberculosis Epidemiologic Studies Consortium #31 – Evaluation of the Domestic Follow-up of Children with Latent TB Infection Diagnosed During Overseas Screening for Permanent Residency in the United States. Funding Agency: CDC. 10/01/09– 9/30/2011
15. Tuberculosis Epidemiologic Studies Consortium. A multicenter prospective comparison of the tuberculin skin test vs. interferon gamma release assays in diagnosing latent tuberculosis infection and in predicting progression from to active tuberculosis. P.I. Robert Belknap 2014-2021. CDC. 9/15/11 – 9/14/21

PUBLICATIONS

Abstracts

1. Reves R. Primary multiple drug-resistant tuberculosis in Mississippi: Epidemiology of a school and community outbreak. Published in the program of: Epidemic Intelligence Service Conference, Centers for Disease Control, Atlanta, GA, April 1978.
2. Reves RR, Robinson P. Pneumonia outbreak in a Mississippi elementary school, probably due to *M. pneumoniae*. Published in the program of: Epidemic Intelligence Service Conference, Centers for Disease Control, Atlanta, GA, April 1979.
3. Reves RR, Murray BE, Armes D, Bartlett AV, Pickering LK. High levels of resistance of fecal enterobacteria to TMP and AMP in children in day care centers. Published in the program and abstracts of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28-October 10, 1986, New Orleans, LA.
4. Pickering LK, Bartlett Jr. AV, Reves RR. Surveillance and transmission of rotavirus in children in day care centers in Houston. *Pediatric Research* 21:332A, 1987.
5. Reves RR, Murray BE, Fong M, Pickering LK. Trimethoprim-resistant (TMP^r) *E. coli* in stool specimens from children in day care centers (DCC). *Pediatric Research* 21:332A, 1987.

6. Denson SE, Gresik MV, Werch JB, Reves RR, Bracey AW, Pickering LK. "Look Back" Program: Experience with the pediatric population in Houston, Texas. *Pediatr Res* 23:367A, 1988.
7. Reves RR, Morrow AL, Bartlett AV, III, Pickering LK. A case-control study of acute diarrhea in children in a health maintenance organization (HMO): Risk estimates associated with nonbreastfeeding and day care. Society for Pediatric Research. Washington, DC; May 1988.
8. Reves RR, Morrow AL, Bartlett AV, Pickering LK. Case control study of risk factors for acute diarrhea among children visiting a health maintenance organization clinic. Published in the program and abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, 23-26, October 1988, Los Angeles, CA.
9. Reves RR, Murray BE, Fong M, Pickering LK. High prevalence of fecal colonization with trimethoprim-resistant *Escherichia coli* associated with attending day care centers in Houston. Published in the program and abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, 23-26 October 1988, Los Angeles, CA.
10. Wanger A, Reves RR, Baker C, Denson S, Larocco M. Clindamycin susceptible, latex agglutination (LA), negative methicillin-resistant *Staphylococcus aureus* (MRSA) recovered from neonates: Comparison of antibiogram phage typing and plasmid pattern analysis. Published in the program and abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17-20 September 1989, Houston, TX.
11. Reves RR, Singh K, Fornacini M, Murray BE, Pickering LK. A prospective study of fecal colonization with multi-resistant *Escherichia coli* (MREC) among children attending day care centers (DCC) in Houston. Society for Pediatric Research. Washington, DC; May 1989.
12. Singh KV, Reves RR, Pickering LK, Murray BE. Diversity of trimethoprim resistance (TMP^r) genes and strains of fecal *E. coli* in day care centers (DCC). Published in the program and abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17-20 September 1989, Houston, TX.
13. Fornasini M, Reves RR, Singh KV, Pickering LK, Murray BE. A prospective study of fecal colonization with multi-resistant *Escherichia coli* (MREC) among children attending day care Centers (DCC) in Houston. Published in the program and abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17-20 September 1989, Houston, TX.
14. Staat M, Morrow AL, Reves RR, Pickering LK. Diarrhea in children newly enrolled in day care centers (DCC) in Houston. Southern Society for Pediatric Research. New Orleans, LA; January 1990.
15. Jones JA, Reves RR, Pickering LK. Incidence of illnesses prompting physician visits among children in day care. Society for Pediatric Research. Anaheim, CA; May 1990.
16. Staat MA, Morrow AL, Reves RR, Pickering LK. Diarrhea in children newly enrolled in day care centers in Houston. American Public Health Association, New York City; October 1990.
17. Morrow AL, Reves RR, Guerrero ML, Ruiz-Placios G, Pickering LK. Protection against *Giardia* infection by human milk and naturally acquired immunity. Society for Pediatric Research. New Orleans, LA 1991.
18. Reves RR, Stone-Venohr B, Hildred G, Kane S, Cohn D. Utility of paired blood cultures in the diagnosis of disseminated *Mycobacterium avium* complex infection. Abstract PuBB7468. VIII International Conference on AIDS, Amsterdam, The Netherlands 19-24 July 1992.
19. Bessesen M, Stone B, Shlay J, Cynamon M, Reves R. A putative *Mycobacterium* species causing disseminated disease in AIDS. Published in the program and abstracts of the 32th

Interscience Conference on Antimicrobial Agents and Chemotherapy, October 11-14, 1992, Anaheim, California.

20. Hossain MM, Reves RR, Habib M, DuPont HL. The timing of breastfeeding initiation in rural Egyptian infants. American Public Health Association, San Francisco, CA, October 24-28, 1993.
21. Burman WJ, Reves RR. Epidemiology of the recent increase in tuberculosis in Denver, Colorado. 1994 International Conference of the American Lung Association/American Thoracic Society, Boston, MA, May 21-25, 1994. Am Rev Respir Dis 149 (suppl):A704, 1994.
22. Burman C, Burman WJ, Reves RR. Cost benefit analysis of directly-observed therapy versus self-administered therapy for tuberculosis. Abstract published in the program of Frontiers of Mycobacteriology 1994, Vail, CO.
23. Burman WJ, Rietmeijer CAM, Reves RR. Treatment of disseminated *Mycobacterium avium* complex (DMAC) with clarithromycin decreases transfusional requirements (Abstract). The Second National Conference on Human Retroviruses and Related Infections January 29-February 2, 1995, Washington, DC.
24. Falloun J, Follansbee S, Reves RR, Weinberg W, Torres R, Chan C, Covington D, Dohn M, Lafon S, Rogers M. Atovaquone suspension for *Pneumocystis pneumonia* (Abstract). The Second National Conference on Human Retroviruses and Related Infections January 29 - February 2, 1995, Washington D.C.
25. Stone B, Burman WJ, Wilson ML, Reves RR, El-Haj H, Bates JH, Cave MD. False-positive cultures for tuberculosis: a 6 year study using DNA fingerprinting. 1995 International Conference of the American Thoracic Society, Seattle, WA, May 20-24, 1995. Am Rev Respir Dis 151 (suppl): A149, 1995.
26. Burman WJ, Reves R, Reitmeijer C. The effectiveness of short-term incarceration for highly-noncompliant tuberculosis patients. 1995 International Conference of the American Thoracic Society, Seattle, WA, May 20-24, 1995. Am Rev Respir Dis 151 (suppl): A555, 1995.
27. Burman WJ, Reves RR, Stone B, El-Haj H, Bates JH, Cave MD. The molecular epidemiology of tuberculosis in Denver, Colorado: a five year study. 1995 International Conference of the American Thoracic Society, Seattle, WA, May 20-24, 1995. Am Rev Respir Dis 151 (suppl): A666, 1995.
28. Wilson ML, Stone BL, Hildred MV, Reves RR. Prolonged incubation of blood and bone marrow cultures with the BACTEC TB system does not increase microbial recovery. Abstract C-123. Presented 22 May, 1995 at the 95th General Meeting, American Society for Microbiology, Washington, DC.
29. Burman W, Morgan M, Stone B, Reves R, Rietmeijer C. Apparent transient *Mycobacterium avium* bacteremia: incidence, laboratory features, and clinical correlates. Abstract 175. Third Conference on Retroviruses and Opportunistic Infections, Washington DC, January 28 - February 2, 1996.
30. Burman W, Reves R, Rietmeijer C, Stone B, Cohn D. Relapse of disseminated *Mycobacterium avium* complex disease and emergence of clarithromycin resistance despite treatment with a multidrug regimen. Abstract 176. Third conference on Retroviruses and Opportunistic Infections, Washington DC, January 28 - February 2, 1996.
31. Burman W, Stone B, Morgan M, Reves R, Wilson M. Comparison of BACTEC 12B vs, solid media for the recovery of *Mycobacterium avium* complex from blood cultures in AIDS patients. Abstract 177. Third Conference on Retroviruses and Opportunistic Infections, Washington DC, January 28 - February 2, 1996.
32. Burman W, Stone B, Reves R, Wilson M, Cave D, Yang ZH, Bates J. False-positive cultures for *Mycobacterium tuberculosis* due to cross-contamination from a laboratory proficiency

- survey specimen. 1996 International Conference of the American Thoracic Society, New Orleans, LA, May 10-15, 1996. *Am J Respir Crit Care Med* 153 (suppl): A36, 1996.
33. Burman W, Reves R, Hawkes A, El-Hajj H, Yang ZH, Bates J, Cave D. The use of a second DNA fingerprinting technique (pTBN12) decreases clustering of *Mycobacterium tuberculosis* isolates and improves the correlation between molecular and conventional epidemiology. 1996 International Conference of the American Thoracic Society, New Orleans, LA, May 10-15, 1996. *Am J Respir Crit Care Med* 153 (suppl): A409, 1996.
 34. Burman W, Maslow J, Stone B, Reves R. Failure of therapy for disseminated *Mycobacterium avium* complex (MAC) may represent acquisition of resistance to clarithromycin or infection with a second strain of MAC. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 22-28, 1997.
 35. Hammer J, Jarboe E, Stone B, Burman W, Reves R. The utility of clarithromycin disk susceptibility testing in the management of HIV-associated disseminated *M. avium* complex infection. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 22-28, 1997.
 36. Reves R, Burman W, Dalton C, Cohn D, Butler J. A cost effectiveness analysis of directly observed therapy versus self administered therapy for treatment of tuberculosis. 1997 ALA/ATS International Conference, San Francisco, California, May 17-21, 1997. *Am J Respir Crit Care Med* 155 (suppl): A33, 1997.
 37. Hammer J, Reves R, Catlin B, Williams L, Sparling J, Beller M, Yang Z, Cave D. Investigation and management of a tuberculosis outbreak among musicians on an international tour. 1997 ALA/ATS International Conference, San Francisco, CA, May 17-21, 1997. *Am J Respir Crit Care Med* 155 (suppl): A559, 1997.
 38. Reves R, Stone B, Fennelly K. Evaluation of tuberculosis isolation practices in a community hospital. 1997 ALA/ATS International Conference. San Francisco, California, May 17-21, 1997. *Am J Respir Crit Care Med* 155 (suppl): A559, 1997.
 39. Buchman L, Burman W, Reves R, Rietmeijer C, Cave D. Evaluating DNA fingerprint clusters of *Mycobacterium tuberculosis* using a geographic information system. 1997 ALA/ATS International Conference, San Francisco, California, May 17-21, 1997. *Am J Respir Crit Care Med* 155 (suppl): A226, 1997.
 40. Burman W, Cohn D, Rietmeijer C, Judson F, Sbarbaro J, Reves R. Noncompliance with directly observed therapy for tuberculosis. 1997 ALA/ATS International Conference, San Francisco, California, May 17-21, 1997. *Am J Respir Crit Care Med* 155 (suppl): A683, 1997.
 41. Cohn DL, Davidson AJ, Burman WJ, Reves RR. Decreases in HIV-related morbidity, mortality, and health care utilization related to highly-active antiretroviral therapy (HAART). 12th International AIDS Meeting; 1998. Geneva, Switzerland.
 42. Reves RR, Page WQ, Burman WJ. Severe noncompliance with tuberculosis treatment: a survey of the frequency, risk-factors, and management practices among programs in the United States of America. *Intl J Tuberc Lung Dis* 2(suppl 2):S347, 1999.
 43. Buchman L, Burman W, Reves R. Interstate noncompliance with treatment of active tuberculosis. 1999 ALA/ATS International Conference, San Diego, California, April 23-28. *Am J Respir Crit Care Med* 159(2): A224, 1999.
 44. Terra M, Burman W, Breese P, Reves R, Cohn D. Streptomycin vs. ethambutol as the fourth drug in highly intermittent, directly-observed tuberculosis treatment(abstract). *Am J Respir Crit Care Med* 2001; 163(suppl):A498.
 45. Terra M, Burman W, Breese P, Cohn D. Incidence and severity of hepatotoxicity during tuberculosis treatment(abstract). *Am J Respir Crit Care Med* 2001; 163(suppl):A498.
 46. Terra M, Burman W, Breese P, Reves R, Cohn D. Six-month, intermittent, directly-observed therapy for isoniazid-resistant tuberculosis(abstract). *Am J Respir Crit Care Med* 2001; 163(suppl):A498.

47. Terra M, Burman W, Breese P, Reves R, Cohn D. Lack of toxicity during concomitant directly-observed isoniazid and disulfiram. *Am J Respir Crit Care Med* 2001; 163(suppl):A104.
48. Kong PM, Tapy J, Calixto P, Burman W, Reves R, Cave MD. A tuberculin-skin test screening program decreases tuberculosis transmission among the homeless. *Am J Respir Crit Care Med* 2001; 163(suppl):A804.
49. Reves R, Huddle M, Burman W. Estimating the potential impact of failure to diagnosis and treat latent tuberculosis infection in a low-incidence urban area(abstract). *Am J Respir Crit Care Med* 2001; 163(suppl):A804.
50. Khan A, Reves R, Sterling T, Vernon A. Weight, body mass index, and treatment outcome in a large TB treatment trial. *Am J Respir Crit Care Med* 2002; 165(suppl):A293.
51. Reves RR, Jasmer RM, Lobato MN, Leary L, and the 2RZ Workgroup. Safety and adherence of closely-monitored 20month rifampin-pyrazinamide treatment for latent tuberculosis infection in homeless persons. *Am J Respir Crit Care Med* 2002; 165(suppl):A713
52. Yun L, Burman WJ, Cohn DL, Cave MD, Reves RR. Persistence of tuberculosis in a low incidence metropolitan area: Lack of progress toward TB elimination in Denver, Colorado despite evidence of decreasing transmission. (abstract). *Am J Respir Crit Care Med* 2003; 167(suppl):A607.
53. Lehman D, Mills J, Sorensen C, Whitesel J, Reves R. Tuberculosis presenting as a prostatic-rectal fistula in an HIV patient *JGIM* 2003; 18(suppl 1): 70.
54. Yun L, Ogle J, Cohn D, Burman W, O'Neill M, Reves R. Barriers to pediatric tuberculosis elimination in a low-incidence area: Denver, Colorado. *Am J Respir Crit Care Med* 2004;169(suppl):A233.
55. Vernon D, Burman W, Yun L, Reves R. Paradoxical reactions in the treatment of nodal tuberculosis. *Am J Respir Crit Care Med* 2004; 169(suppl):A235.
56. Belknap RW, Yun LW, Reves RR, Cohn DL, Burman WJ. Tuberculosis and HIV Co-infection in a low incidence area: Denver, 1984-2002. *Am J Respir Crit Care Med* 2004; 169(suppl):A375.
57. Baron E, Belknap R, McEwen D, Yun L, Reves R. Missed opportunities for timely diagnosis and treatment of latent tuberculosis in patients within Denver Health and Hospitals. *Am J Respir Crit Care Med* 2005;171(suppl):A270.
58. Belknap R, Stone B, Burman W, Reves R. Successful implementation of a state regulation requiring directly observed therapy for active pulmonary tuberculosis. *Am J Respir Crit Care Med* 2005;171(suppl):A273.
59. Yun L, Belknap R, Lin R, Reves R. Impact of immigration screening on TB rates in foreign-born persons during the first year after arrival. *Am J Respir Crit Care Med* 2005;171(suppl):A551.
60. Cronin W, Abernethy N, Davidow A, Katz D, Pascopella L, Reves R, Royce S, and the Tuberculosis Epidemiologic Studies Consortium. The contribution of pre-entry immigration medical examinations to tuberculosis control in the United States. *Am J Respir Crit Care Med* 2007;175(suppl):A25.
61. R Belknap, J Kelaher, K Wall, C Daley, N Schluger, and R Reves. Diagnosis of Latent Tuberculosis Infection in U.S. Health Care Workers: Reproducibility, Repeatability and 6 Month Follow-Up with Interferon-gamma Release Assays (IGRAs). *Am. J Respir Crit Care Med* 2009;179:A4101.
62. Amy L. Davidow, Anna Sevilla, Dolly Katz, Randall Reves, and T B. Epidemiologic Studies Consortium. Prevention Of Tuberculosis In Older, Foreign-born Residents Of The US *Am J Respir Crit Care Med* 2010;181:A5381.

63. Robert Belknap, Kirsten Wall, Larry Teeter, Susan Dorman, Paul Weinfurter, Randall Reves, and Charles L. Daley. Interferon-gamma Release Assays (IGRAs) In Serial Testing For Latent Tuberculosis Infection In U.S. Health Care Workers
Am J Respir Crit Care Med 2010;181:A2263.
64. Robert Belknap, Laurie Luna, Randall Reves, Le Turk, Stephen Weiss, Kit Yee Au-Yeung, Greg Moon, and Erika Karplus. EMITTER 2.0: Feasibility Of A Microchip-based System For Electronically Observed Tuberculosis Therapy
Am J Respir Crit Care Med 2010;181:A5462.
65. Peter Oh, Amy Davidow, Randall Reves, Ed A. Graviss, Rachel A. Royce, Dolly Katz, and For The Tuberculosis Epidemiologic Studies Consortium. The Contribution Of Prevalent Cases To The Reported Tuberculosis Case Load Among Newly-Arrived Foreign-Born Persons In The United States. Am J Respir Crit Care Med 2011;183:A1845.
66. Randall Reves, Carol D. Hamilton, Jan Tapy, Masa Narita, Ryan P. Kyle, Charles Heilig, Lorna Bozeman, and Stefan Goldberg. Evaluating The Efficacy And Safety Of Intermittent Tuberculosis (TB) Treatment When Isoniazid (INH) Cannot Be Used. Am J Respir Crit Care Med. 2011;183:A4040.
67. Erin Bliven-Sizemore, Timothy R. Sterling, Nong Shang, Debra Benator, Kevin Schwartzman, Randall Reves, Jan Drobeniuc, Philip Spradling, and Elsa Villarino. Hepatitis C Virus Infection And Female Sex Are Risk Factors For Treatment Limiting Hepatotoxicity In A Large Clinical Trial Of Treatment Of Latent Tuberculosis Infection: Results Of A Nested Case-Control Study. Am J Respir Crit Care Med 2011;183:A4041.
68. Robert Belknap, Matt Parker, Yaping Wang, Susan Dorman, Ed Graviss, Paul Weinfurter, Charles Daley, and Randall Reves. Re-Running Quantiferon-TB Gold In-Tube Samples As A Strategy For Identifying False Positive Results. Am J Respir Crit Care Med. 2011;183:A1187.
69. Jacob M. Gray, Randall Reves, Steven Johnson, and Robert Belknap. High Frequency Of Discordant QuantiFERON-TB Gold In-Tube Results When Serially Testing HIV Patients At Low Risk For TB Exposure. Am J Respir Crit Care Med. 2011;183:A1188.
70. Jacob M. Gray, Randall Reves, and Robert Belknap. Improvement In Latent Tuberculosis Testing Of HIV Patients After Switching From The Tuberculin Skin Test To Quantiferon-TB Gold-In-Tube Am J Respir. Crit Care Med. 2011;183:A1197.
71. Nicholas D. Walter, John Painter, Jennifer Flood, Yunxin Fu, Kirsten Wall, Matthew Parker, Philip Lowenthal, Redentor Asis, and Randall Reves. Impact Of Enhanced Pre-Immigration Evaluation On Diagnosis Of Tuberculosis In California: A Retrospective Cohort Study Of Filipino Immigrants Based On Electronic Linkage Am. J. Respir. Crit. Care Med. 2012; 185: A2330.

Referred Original Articles in Journals

1. Reves RR, Blakely D, Snider D, Farer L. Transmission of multiple drug-resistant tuberculosis: Report of a school and community outbreak. Am J Epidemiology 113:423-435, 1981.
2. DuPont HL, Reves RR, Galindo E, Sullivan PS, Mendiola JG. Treatment of travelers' diarrhea with trimethoprim sulfamethoxazole and with trimethoprim alone. N Engl J Med 307:841-844, 1982.
3. Reves RR, Bass P, DuPont HL, Sullivan P, Mendiola J. Failure to demonstrate effectiveness of an anticholinergic drug in the symptomatic treatment of acute travelers' diarrhea. J Clin Gastroenterol 5:223-227, 1983.
4. Reves RR. Declining fertility in England and Wales as a major cause of the twentieth century decline in mortality: The role of changing family size and age structure in infectious disease mortality in infancy. Am J Epidemiol 112:112-126, 1985.

5. Reves RR, Budgett R, Miller D, Woodsworth J, Haines A. Study of middle ear disease using tympanometry in general practice. *Br Med J* 290:1953-1956, 1985.
6. Reves RR, Murray BE, Pickering LK, Prado D, Maddock M, Bartlett AV. Children with trimethoprim and ampicillin-resistant fecal *Escherichia coli* in day care centers. *J Infect Dis* 156:758-762, 1987.
7. Ad Hoc Working Group for Critical Appraisal of the Medical Literature. A proposal for more informative abstracts of clinical articles. *Ann Intern Med* 106:598-604, 1987.
8. Pickering LK, Bartlett AV III, Reves RR, Morrow A. Asymptomatic excretion of rotavirus before and after rotavirus diarrhea in children in day care centers. *J Pediatr* 112:361-365, 1988.
9. Reves RR, Johnson PC, Ericsson CD, DuPont HL. A cost effectiveness comparison of the use of antimicrobial agents for treatment of prophylaxis of travelers' diarrhea. *Arch Intern Med* 148:2421-27, 1988.
10. Bartlett AV, Reves RR, Pickering LK. Rotavirus in infant-toddler day care centers: Epidemiology relevant to disease control strategies. *J Pediatr* 113:435-41, 1988.
11. Denson SE, Gresik MV, Werch JB, Reves RR, Bracey AW, Hoots WK, Pickering LK. "Look Back" Program: Experience with the pediatric population in Houston, Texas. *Ped Infect Dis J* 7(8):596-598, 1988.
12. Reves RR, Hossain MM, Midthun K, Kapikian AZ, Naguib T, Wyatt RG, Zaki AM, DuPont HL. An observational study of naturally acquired immunity to rotaviral diarrhea in a cohort of 363 Egyptian children: Calculation of risk for second episodes using age-specific person-years of observation. *Am J Epidemiology* 130:981-988, 1989.
13. Murray BE, Mathewson JJ, DuPont HL, Ericsson CD, Reves RR. Emergence of antimicrobial resistant fecal *Escherichia coli* in travelers not taking prophylactic antimicrobial agents. *Antimicrob Agents Chemother* 34:515-518, 1990.
14. Reves RR, Fong M, Pickering LK, Bartlett III A, Alvarez M, Murray BE. Risk factors for fecal colonization with trimethoprim- and multi-resistant *Escherichia coli* among children in day care centers in Houston. *Antimicrob Agents Chemother* 34:1429-1434, 1990.
15. Novak RD, Smolensky MH, Fairchild EJ, Reves RR. Shiftwork and industrial injuries at a chemical plant in southeast Texas. *Chronobiology International* 7:155-64, 1990.
16. Morrow AL, Benton M, Reves RR, Pickering LK. Knowledge and attitudes of day care center (DCC) parents and care providers regarding children infected with human immunodeficiency virus (HIV). *Pediatr* 87:876-883, 1991.
17. Van R, Morrow AL, Reves RR, Pickering LK. Environmental contamination in child day care centers. *Am J Epidemiol* 133:460-470, 1991.
18. Singh KV, Reves RR, Pickering LK, Murray BE. Comparative *in vitro* activities of amoxicillin/clavulanic acid, cefuroxime, cephalexin, and cephalothin against *Escherichia coli* isolates resistant to multiple antibiotics. *Antimicrob Agents Chemother* 34:2047-2049, 1990.
19. Staat MA, Morrow AL, Reves RR, Bartlett AV, Pickering LK. Diarrhea in children newly enrolled in day care centers in Houston. *Pediatr Infect Dis J* 10:282-286, 1991.
20. Morrow AL, Reves RR, West MS, Guerrero ML, Ruiz-Palacios GM, Pickering LK. Protection against infection with *Giardia lamblia* by breastfeeding in a cohort of Mexican infants. *J Pediatr* 121:363-70, 1992.
21. Fornasini M, Reves RR, Murray BE, Morrow AL, Pickering LK. Trimethoprim-resistant *Escherichia coli* in households of children attending day care centers. *J Infect Dis* 166:326-330, 1992.

22. Singh KV, Reves RR, Pickering LK, Murray BE. Identification by DNA sequence analysis of a new plasmid-encoded trimethoprim resistance gene in fecal *Escherichia coli* isolates from children in day-care centers. *Antimicrob Agents Chemother* 36:1720-26, 1992.
23. Herrera CR, Moss JT, Reves RR, Buffler PA. Feasibility study of surveying the adverse drug reaction surveillance systems in a large community of hospitals. *Annals of Pharmacotherapy* 26:384-91, 1992.
24. Reves RR, Morrow AL, Bartlett AV, Caruso CJ, Plumb RL, Lu BT, Pickering LK. Child day care increases the risk of clinic visits for acute diarrhea and diarrhea due to rotavirus. *Am J Epidemiology* 137:97-107, 1992.
25. Bessesen, MT, Shlay J, Stone-Venohr B, Reves RR, Cohn DL. Disseminated *Mycobacterium genavense* infection: Clinical and microbiologic features and response to therapy. *AIDS* 7:1357-1361, 1993.
26. Stone BL, Cohn DL, Kane MS, Hildred MV, Wilson ML, Reves RR. Utility of paired blood cultures and smears in the diagnosis of disseminated *Mycobacterium avium* complex infections in AIDS patients. *J Clin Micro* 32:841-842, 1994.
27. Hossain MM, Reves RR, Radwan MM, Arafa SA, Habib M, DuPont HL. Breast-feeding patterns and their correlates in a cohort of rural Egyptian infants. *JR Soc Health* 114:290-296, 1994.
28. Hossain MM, Reves RR, Radwan MM, Habib M, DuPont HL. The timing of breast-feeding initiation and its correlates in a cohort of rural Egyptian infants. *J Trop Pediatr* 41:354-359, 1995.
29. Burman WJ, Cohn DL, Reves RR, Wilson ML. Multifocal cellulitis and monoarticular arthritis as manifestations of *Helicobacter cinaedi* bacteremia. *Clin Infect Dis* 20:654-70, 1995.
30. Wilson ML, Stone BL, Hildred MV, Reves RR. Comparison of recovery rates for mycobacteria from BACTEC 12B vials, Middlebrook 7H11-selective 7H11 biplates, and Lowenstein-Jensen slants in a Public Health Mycobacteriology Laboratory. *J Clin Microbiol* 33:2516-18, 1995.
31. DeGroote MA, Visvesvara G, Wilson ML, Pieniazek NJ, Slemenda SB, daSilva AJ, Leitch GJ, Bryan RT, Reves RR. Polymerase chain reaction and culture confirmation of disseminated *Encephalitozoon cuniculi* in a patient with AIDS: successful therapy with albendazole. *J Infect Dis* 171:1375-8, 1995.
32. Wilson ML, Stone BL, Hildred MV, Reves RR. Prolonged incubation of blood and bone marrow cultures in 12B bottles processed on the BACTEC 460 TB System does not increase microbial recovery. *Diag Microbial Infect Dis* 25:113-5, 1996.
33. Saravolatz LD, Winslow DL, Collins G, Hodges JS, Pettinelli C, Stein DS, Markowitz N, Reves R, Loveless MO, Crane L, Thompson M, Abrams D, and investigators for the Terry Bein Community Programs for Clinical Research on AIDS. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. *N Engl J Med* 335:1099-106;1996.
34. Burman WJ, Stone BL, Reves RR, Wilson ML, Yang ZH, El-Hajj H, Bates JH, Cave MD. The incidence of false-positive cultures for *Mycobacterium tuberculosis*. *Am J Respir Crit Care Med* 155:321-6, 1997.
35. Burman WJ, Reves RR, Hawkes AP, Rietmeijer CA, Yang Z, El-Hajj H, Bates JH, Cave MD. DNA fingerprinting with two probes decreases clustering of *Mycobacterium tuberculosis*. *Am J Respir Crit Care Med* 155:1140-58, 1997.

36. Stone BL, Burman WJ, Hildred MV, Jarboe EA, Reves RR, Wilson ML. The diagnostic yield of AFB smear-positive sputum specimens. *J Clin Microbiol* 35:1030-1,1997.
37. Burman WJ, Cohn DL, Rietmeijer CA, Judson FN, Sbarbaro JA, Reves RR. Noncompliance with directly-observed therapy for tuberculosis: epidemiology and effect on the outcome of treatment. *Chest* 111:1168-73,1997.
38. Burman WJ, Cohn DL, Rietmeijer CA, Judson FN, Sbarbaro JA, Reves RR. Short-term incarceration for the management of noncompliance with tuberculosis treatment. *Chest* 112:57-62,1997.
39. Burman WJ, Dalton CB, Cohn DL, Butler JR, Reves RR. A cost-effectiveness analysis of directly-observed therapy versus self-administered therapy for treatment of tuberculosis. *Chest* 112:63-70, 1997.
40. Burman WJ, Reves RR, Rietmeijer CA, Cohn DL. A retrospective comparison of clarithromycin vs rifampin in combination therapy for disseminated *M. avium* complex disease in AIDS: clarithromycin decreases transfusion requirements. *Intl J Tuberc Lung Dis* 1:163-9,1997.
41. Jarboe E, Stone BL, Burman WJ, Wallace RJ Jr, Brown BA, Reves, RR, Wilson ML. Evaluation of a disk-diffusion method for determining susceptibility of *Mycobacterium avium* complex to clarithromycin. *Diag Micro Infect Dis*, 1998;30:197-203.
42. Burman WJ, Stone BL, Rietmeijer CA, Maslow J, Cohn DL, Reves RR. Long-term outcomes of treatment of *Mycobacterium avium* complex bacteremia using a clarithromycin-containing regimen. *AIDS*, 1998;12:1309-1315.
43. Burman WJ, Reves RR, Cohn DL. The case for conservative management of early HIV disease. *JAMA* 1998;280:93-5.
44. Fouty B, Ferman F, Reves R. Riboflavin to treat nucleoside analogue-induced lactic acidosis. *Lancet* 352:291-2,1998.
45. Agerton TB, Valway SE, Blinkhorn RJ, Shilkret KL, Reves R, Schluter WW, Gore B, Pozsik CJ, Plikaytis BB, Woodley C, Onorato IM. Spread of Strain W, a highly drug-resistant strain of *Mycobacterium tuberculosis*, across the United States. *Clin Infect Dis* 1999;29:85-92.
46. Chan ED, Reves R, Belisle JT, Brennan PJ, Hahn WE. Diagnosis of tuberculosis by a visually detectable immunoassay for lipoarabinomannan. *Am J Respir Crit Care Med* 2000;161:1713-19.
47. Burman WJ, Reves RR. A review of false-positive cultures for *Mycobacterium tuberculosis* and recommendations for avoiding unnecessary treatment. *Clin Infect Dis* 2000;31:1390-5.
48. Burman WJ, Reves RR, Cohn DL, Schooley RT. Breaking the camel's back: multicenter clinical trials and local institutional review boards. *Ann Intern Med* 2001;134:152-7.
49. Reichler MR, Reves R, Bur S, Thompson V, Mangura BT, Ford J, Valway SE, Onorato IM. An evaluation of investigations conducted to detect and prevent transmission of tuberculosis. *JAMA* 2002;287:991-995.
50. Reichler MR, Reves R, Bur S, Ford J, Thompson V, Mangura B, Onorato IM, Valway SE. Treatment of latent tuberculosis infections in contacts of tuberculosis cases in the US. *Southern Med J* 2002;95:414-20.

51. Kong, Po-Marn, Tapy J, Calixto P, Burman WJ, Reves RR, Yang Z, Cave MD. Skin-test screening and tuberculosis transmission among the homeless. *Emerg Infect Dis* 2002; 8: 1280-4.
52. Burman WJ. Terra M. Breese P. Cohn D. Reves R. Lack of toxicity from concomitant directly observed disulfiram and isoniazid-containing therapy for active tuberculosis. *Intl J Tuberc Lung Dis* 2002;6:839-42.
53. Blumberg HM. Burman WJ. Chaisson RE. Daley CL. Etkind SC. Friedman LN. Fujiwara P. Grzemska M. Hopewell PC. Iseman MD. Jasmer RM. Koppaka V. Menzies RI. O'Brien RJ. Reves RR. Reichman LB. Simone PM. Starke JR. Vernon AA. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. *American Journal of Respiratory & Critical Care Medicine. Am J Respir Crit Care Med* 2003;167:603-62.
54. Reichler MR, Bur S, Reves R, Mangura B, Thompson V, Ford J, Castro KG. Results of testing for human immunodeficiency virus infection among recent contacts of infectious tuberculosis cases in the United States. *Int J Tuberc Lung Dis.* 2003;7:S471-8.
55. Davidow AL, Mangura BT, Wolman MS, Bur S, Reves R, Thompson V, Ford J, Reichler MR. Workplace contact investigations in the United States. *Int J Tuberc Lung Dis.* 2003;7:S446-52.
56. Yun LW, Reves RR, Reichler MR, Bur S, Thompson V, Mangura B, Ford J. Outcomes of contact investigation among homeless persons with infectious tuberculosis. *Int J Tuberc Lung Dis.* 2003;7:S405-11.
57. Lambert L, Rajbhandary S, Quails N, Budnick L, Catanzaro A, Cook S, Daniels-Cuevas L, Garber E, Reves R. Costs of implementing and maintaining a tuberculin skin test program in hospitals and health departments. *Infect Control Hosp Epidemiol.* 2003;24:814-20.
58. Burman WJ, Breese PE, Murray BE, Singh KV, Batal HA, MacKenzie TD, Ogle JW, Wilson ML, Reves RR, Mehler PS. Conventional and molecular epidemiology of trimethoprim-sulfamethoxazole resistance among urinary *Escherichia coli* isolates. *Am J Med.* 2003;115:358-64.
59. Lobato MN, Reves RR, Jasmer RM, Grabau JC, Bock NN, Shang N; 2RZ Study Group. Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons. *Chest* 2005; 127:1296-303.
60. Belknap R, Reves R, Burman W. Immune reconstitution to *Mycobacterium tuberculosis* after discontinuing infliximab. *Int J Tuberc Lung Dis.* 2005; 9:1057-8.
61. Gessler D, Dye C, Farmer P, Murray M, Navin T, Reves R, Shinnick T, Small PM, Yates T, Simpson G. Public health. A National Tuberculosis Archive. *Science.* 2006; 311:1245-6.
62. Awal K, Sterling TR, Reves R, Vernon A, Horsburgh CR, the Tuberculosis Trials Consortium. Lack of weight gain and relapse risk in a large tuberculosis treatment trial. *Am J Respir Crit Care Med.* 2006 Aug 1; 174:344-8.
63. Mazurek GH, Weis SE, Moonan PK, Daley CL, Bernardo J, Lardizabal AA, Reves RR, Toney SR, Daniels LJ, LoBue PA. Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma release assays in persons with suspected tuberculosis. *Clin Infect Dis.* 2007;45:837-45.

64. Kestler M, Reves R, Belknap R. Pacemaker wire infection with *Mycobacterium tuberculosis*: a case report and literature review. *Int J Tuberc Lung Dis.* 2009;13:272-4.
65. Davidow AL, Katz D, Reves R, Bethel J, Ngong L; Tuberculosis Epidemiologic Studies Consortium. The challenge of multisite epidemiologic studies in diverse populations: design and implementation of a 22-site study of tuberculosis in foreign-born people. *Public Health Rep.* 2009;124:391-9.
66. Kellar KL, Gehrke J, Weis SE, Mahmutovic-Mayhew A, Davila B, Zajdowicz MJ, Scarborough R, LoBue PA, Lardizabal AA, Daley CL, Reves RR, Bernardo J, Campbell BH, Mazurek GH. Multiple cytokines respond to *Mycobacterium tuberculosis* antigens in subjects with culture-confirmed infection. *PLoS One* 2011;6:e26545.
67. Au-Yeung KY, Moon GD, Robertson TL, Dicarlo LA, Epstein MS, Weis SE, Reves RR, Engel G. Early clinical experience with networked system for promoting patient self-management. *Am J Manag Care.* 2011;17:e277-87.
68. Gray J, Reves R, Johnson S, Belknap R. Identification of false-positive QuantiFERON-TB Gold In-Tube assays by repeat testing in HIV-infected patients at low risk for tuberculosis. *Clin Infect Dis.* 2012 Feb 1;54(3):e20-3.
69. Solomon GM, Schmidt, EM, Reves R, Welsh CA. Cough and pleural disease in a Burmese immigrant-a masquerader. *Southwest Journal of Pulmonary and Critical Care* 2012; 4: 205-210.
70. Belknap R, Weis S, Brookens A, Au-Yeung KY, Moon G, Dicarlo L, Reves R. Feasibility of an ingestible sensor-based system for monitoring adherence to tuberculosis therapy. *PLoS One.* 2013;8:e53373.
71. Henao-Martínez AF, Gray JM, González-Fontal GR, Reves R. Intracardiac extra-cavitary primary effusion lymphoma in an HIV-infected patient. *Int J STD AIDS.* 2013 Jan;24(1):78-9. doi: 10.1258/ijsa.2012.012178. PubMed PMID: 24400343.
72. Daley CL, Reves RR, Beard MA, Boyle J, Clark RB, Beebe JL, Catanzaro A, Chen L, Desmond E, Dorman SE, Hudson TW, Lardizabal AA, Kapoor H, Marder DC, Miranda C, Narita M, Reichman L, Schwab D, Seaworth BJ, Terpeluk P, Thanassi W, Kawamura LM. A summary of meeting proceedings on addressing variability around the cut point in serial interferon- γ release assay testing. *Infect Control Hosp Epidemiol.* 2013;34:625-30. doi: 10.1086/670635. Epub 2013 Apr 19. PubMed PMID: 23651895.
73. Painter JA, Graviss EA, Hai HH, Nhung DT, Nga TT, Ha NP, Wall K, Loan le TH, Parker M, Manangan L, O'Brien R, Maloney SA, Hoekstra RM, Reves R. Tuberculosis screening by tuberculosis skin Test or QuantiFERON®-TB Gold In-Tube Assay among an immigrant population with a high prevalence of tuberculosis and BCG vaccination. *PLoS One.* 2013;8:e82727. doi: 10.1371/journal.pone.0082727. PubMed PMID: 24367546.
74. Dorman SE, Belknap R, Graviss EA, Reves R, Schluger N, Weinfurter P, Wang Y, Cronin W, Hirsch-Moverman Y, Teeter LD, Parker M, Garrett DO, Daley CL; for the Tuberculosis Epidemiologic Studies Consortium. Interferon- γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. *Am J Respir Crit Care Med.* 2014;189(1):77-87. doi: 10.1164/rccm.201302-0365OC. PubMed PMID: 24299555.
75. Walter ND, Painter J, Parker M, Lowenthal P, Flood J, Fu Y, Asis R, Reves R; for the TB Epidemiologic Studies Consortium. Persistent latent tuberculosis reactivation risk in US

- immigrants. *Am J Respir Crit Care Med*. 2014;189(1):88-95. doi:10.1164/rccm.201308-1480OC. PubMed PMID: 24308495.
76. Pang J, Teeter L, Katz D, Davidow A, Miranda W, Wall K, Ghosh S, Stein-Hart T, Restrepo B, Reves R, Graviss E. Epidemiology of tuberculosis in young children. *Pediatrics* 2014;133:e494-504. Epub 2014 Feb 10. PubMed PMID: 24515517.
 77. Reves R, Heilig CM, Tapy JM, Bozeman L, Kyle RP, Hamilton CD, Bock N, Narita M, Wing D, Hershfield E, Goldberg SV, and the Tuberculosis Trials Consortium. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance. *Int J Tuberc Lung Dis* 2014;18:571-80. doi: 10.5588/ijtld.13.0304. PubMed PMID: 24903795.
 78. Howley MM, Painter JA, Katz DJ, Graviss EA, Reves R, Beavers SF, Garrett DO; for the Tuberculosis Epidemiologic Studies Consortium. Evaluation of QuantiFERON-TB Gold In-Tube and tuberculin skin tests among immigrant children being screened for latent tuberculosis infection. *Pediatr Infect Dis J*. 2014 Aug 4. PubMed PMID: 25093974.
 79. Davidow AL, Katz D, Ghosh S, Blumberg H, Tamhane A, Sevilla A, Reves R; Tuberculosis Epidemiologic Studies Consortium. Preventing infectious pulmonary tuberculosis among foreign-born residents of the United States. *Am J Public Health*. 2015 Sep;105(9):e81-8. PubMed PMID: 26180947.
 80. Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME; TB Trials Consortium. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. *Int J Tuberc Lung Dis*. 2015 Sep;19(9):1039-44. PubMed PMID: 26260821.
 81. Aiona K, Lowenthal P, Painter JA, Reves R, Flood J, Parker M, Fu Y, Wall K, Walter ND. Transnational record linkage for tuberculosis surveillance and program evaluation. *Public Health Rep*. 2015;130:475-84. PubMed PMID: 26327726
 82. Young KH, Ehman M, Reves R, Peterson Maddox BL, Khan A, Chorba TL, Jereb J. Tuberculosis contact investigations--United States, 2003-2012. *MMWR Morb Mortal Wkly Rep*. 2016;64(50-51):1369-74. PubMed PMID: 26720627.
 83. Walter ND, Miller MA, Vasquez J, Weiner M, Chapman A, Engle M, Higgins M, Quinones AM, Rosselli V, Canono E, Yoon C, Cattamanchi A, Davis JL, Phang T, Stearman RS, Datta G, Garcia BJ, Daley CL, Strong M, Kechris K, Fingerlin TE, Reves R, Geraci MW. Blood transcriptional biomarkers for active tuberculosis among patients in the United States: a case-control study with systematic cross-classifier evaluation. *J Clin Microbiol*. 2016;54:274-82. PubMed PMID: 26582831
 84. Young KH, Ehman M, Reves R, Maddox BL, Khan A, Chorba TL, Jereb J. Tuberculosis Contact Investigations - United States, 2003-2012. *MMWR Morb Mortal Wkly Rep*. 2016;64(50-51):1369-74. PubMed PMID:26720627.
 85. Collins JM, Reves RR, Belknap RW. High Rates of tuberculosis and opportunities for prevention among international students in the U.S. *Ann Am Thorac Soc*. 2016;13:522-8. PubMed PMID: 26730745.
 86. De Groote MA, Higgins M, Hraha T, Wall K, Wilson ML, Sterling DG, Janjic N, Reves R, Ochsner UA, Belknap R. Highly Multiplexed Proteomic Analysis of Quantiferon Supernatants To Identify Biomarkers of Latent Tuberculosis Infection. *J Clin Microbiol*. 2017 Feb;55(2):391-402. doi: 10.1128/JCM.01646-16. Epub 2016 Nov 16. Erratum in: *J Clin Microbiol*. 2017 May;55(5):1598.

87. Gaensbauer J, Aiona K, Haas M, Reves R, Young J, Belknap R. Better Completion of Pediatric Latent Tuberculosis Treatment Using 4 Months of Rifampin in a US-Based Tuberculosis Clinic. *Pediatr Infect Dis J*. 2018 Mar;37:224-228. PubMed PMID: 28777204.
88. Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dedicoat M, Erkins C, Escalante P, Falzon D, Garcia-Prats AJ, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh WJ, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, Schaaf HS, Skrahina A, Soolingen DV, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang JY, Yoshiyama T, Menzies D. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. *Lancet Respir Med*. 2018 Apr;6(4):265-275. PubMed PMID: 29595509.
89. Sosa LE, Njie GJ, Lobato MN, Bamrah Morris S, Buchta W, Casey ML, Goswami ND, Gruden M, Hurst BJ, Khan AR, Kuhar DT, Lewinsohn DM, Mathew TA, Mazurek GH, Reves R, Paulos L, Thanassi W, Will L, Belknap R. Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019. *MMWR Morb Mortal Wkly Rep*. 2019 May 17;68(19):439-443. PubMed PMID: 31099768.
90. Flynn AG, Aiona K, Haas MK, Reves R, Belknap R. Clinical Characteristics of Active Tuberculosis Diagnosed after Starting Treatment for Latent Tuberculosis Infection. *Clin Infect Dis*. 2019 Nov 27. pii: ciz1157. [Epub ahead of print] PubMed PMID: 31773132.
91. Ahmed A, Feng PI, Gaensbauer JT, Reves RR, Khurana R, Salcedo K, Punnoose R, Katz DJ; Tuberculosis Epidemiologic Studies Consortium. Interferon- γ Release Assays in Children <15 Years of Age. *Pediatrics*. 2020 Jan;145(1). pii: e20191930. PubMed PMID: 31892518.

Invited Articles

1. DuPont HL, Ericsson CD, Reves RR, Galindo E. Antimicrobial therapy for travelers' diarrhea. *Rev Infect Dis* 8:S217-S222, 1986.
2. Reves RR, Pickering LK. Today's strategy for managing viral pneumonia. *J Respir Dis* 8:39-47, 1987.
3. Reves RR, Pickering LK. Infections in child day care centers as they relate to Internal Medicine. *Annual Review of Medicine* 41:383-391, 1990.
4. Reves RR, Pickering LK. Impact of child day care on infectious diseases in adults. *Infect Dis Clin North Am* 6:239-250, 1992.
5. Osterholm MT, Reves RR, Murphy JR, Pickering LK. Infectious diseases and child day care. *Pediatr Infect Dis J* 11:S31-S41, 1992.
6. Chee CBE, Reves R, Zhang Y, Belknap R. Latent tuberculosis infection: Opportunities and challenges. *Respirology*. 2018;23:893-900. Review. PubMed PMID: 2990

Chapters

1. Septimus ES, Reves RR. Osteomyelitis. In *Infectious Diseases of Children and Adults: A Step-by-Step Approach*, Addison-Wesley Publishing Corp., Park, CA, 1985.

2. Pickering LK, Reves RR. Hospital acquired infection in the pediatric patient: Diarrhea. In Hospital Acquired Infection in the Pediatric Patient, ed. LG Donowitz. Williams and Wilkins, Baltimore, MD, 1988.
3. Kozinetz CA, Crane MP, Reves RR. Pediatric H.I.V. Infections and AIDS: Epidemiology. In Seminars in Pediatric Infectious Diseases, ed. RD Feigin, WB Saunders, Philadelphia, 1990; 1(No. 1):6-16.
4. Reves RR, Jones J. Antibiotic use and resistance patterns in day care centers. In Seminars in Pediatric Infectious Diseases, ed. RD Feigin, WB Saunders, Philadelphia, 1990;1(No. 2):1-7.
5. Reves RR. Meningitis. In Critical Care Secrets, eds. PE Parsons and JP Wiener-Kronish, Hanley and Belfus, Philadelphia, PA, 1992.
6. Reves RR. Tuberculosis. In Intensive Care Medicine, 3rd ed., eds, JM Rippe, RS Irwin, MP Fink and FB Cerra. Little, Brown and Company, 1996.
7. Reves RR. Urinary Tract Infections. In Primary Care Secrets, ed. J Mladenovic, Hanley and Belfus, Inc., Philadelphia, PA, 1995.
8. Reves RR. Nosocomial Transmission of Tuberculosis. Check Sample MB96-5 (MB-256), Chicago: American Society of Clinical Pathologists, 1996.
9. Lehman D, Reves RR. Meningitis. In Critical Care Secrets, 2nd ed., eds. PE Parsons and JP Wiener-Kronish, Hanley and Belfus, Philadelphia, PA, 1998.
10. Reves RR. Urinary Tract Infections. In Primary Care Secrets, 2nd ed., ed. J Mladenovic, Hanley and Belfus, Inc., Philadelphia, PA, 1998.
11. Reves RR. Tuberculosis. In Intensive Care Medicine, 4th ed., eds, RS Irwin, FB Cerra and JM Rippe. Little, Brown and Company, 1998.
12. Daly JS, Reves RR. Tuberculosis in the Intensive Care Unit. In Manual of Intensive Care Medicine, 3rd ed., eds. RS Irwin and JM Rippe. Lippincott Williams & Wilkins, 2000.
13. Reves RR. Tuberculosis and Other Mycobacterial Diseases. In Conn's Current Therapy, 2001, eds. RE Rakel and ET Bope. WB Saunders Company, 2001.
14. Reves RR. Tuberculosis. In Intensive Care Medicine, 5th ed., eds, RS Irwin and JM Rippe. Lippincott, Williams & Wilkins, Philadelphia, 2002.
15. Reves RR, Lehman D. Urinary Tract Infections. In Primary Care Secrets, 3rd ed., ed. J Mladenovic, Hanley and Belfus, Inc., Philadelphia, PA, 2004.
16. Kasperbauer S, Reves RR. Meningitis. In Critical Care Secrets, 4th ed., eds. PE Parsons and JP Wiener-Kronish. Philadelphia: Hanley and Belfus, 2007.
17. Belknap R, Reves R. Tuberculosis. In Intensive Care Medicine, 6th ed., eds, RS Irwin and JM Rippe. Lippincott, Williams & Wilkins, Philadelphia, 2008.
18. Belknap R, Reves R. Tuberculosis. In Intensive Care Medicine, 6th ed., eds, RS Irwin and JM Rippe. Lippincott, Williams & Wilkins, Philadelphia, 2012.

Other Publications and Editorials

1. Deetz TR, Reves RR, Septimus E. Secondary rash in toxic shock syndrome? N Engl J Med 1981; 304:174.
2. Reves RR, DuPont HL, Sievert W. African trypanosomiasis. MMWR 1983; 32:112-113.

3. Reves RR. Illness in breast- and bottle-fed infants. (Letter). AJDC 1986; 140:185-186.
4. Pickering LK, Reves RR. Editorial: Occupational risks for child-care providers and teachers. JAMA 263:2096-7, 1990.
5. Shawar RM, LaRocco MT, Reves RR. *Neisseria sicca* and *Streptococcus sanguis* I endocarditis in an intravenous drug user. Clinical Microbiology Newsletter 13:18, 1991.
6. Burman WJ, Wilson ML, Reves RR. Specimen contamination in mycobacteriology laboratory detected by pseudo-outbreak of multidrug-resistant tuberculosis: analysis by routine epidemiology and confirmation by molecular technique. J Clin Microbiol 34:3257, 1996.
7. Gessler D, Dye C, Farmer P, Murray M, Navin T, Reves R, Shinnick T, Small PM, Yates T, Simpson G. A national tuberculosis archive. Science. 2006; 311:1245-6.
8. Burman WJ, Reves RR. Editorial: Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers. Am J Respir Crit Care Med 2001;164:1112-3.
9. Burman WJ, Reves RR. Editorial: How much directly observed therapy is enough? Am J Respir Crit Care Med 2004;170:474-5.
10. Reves R. Universal genotyping as a tool for establishing successful partnerships for tuberculosis elimination. Am J Respir Crit Care Med 2006; 174:491-2.
11. Belknap R, Wall K, Reves R. What can the NHANES data tell us about the tuberculin skin test and the risk for active tuberculosis? Am J Respir Crit Care Med. 2008;178:883-4. Letter to the editor
12. Reves RR, Burman WJ. Sorting out icebergs, mirages, and clinical tuberculosis during active case finding. Am J Respir Crit Care Med. 2009 Dec 15;180(12):1167-9. Editorial.
13. Reves RR, Nolan CM. Tuberculosis elimination in the United States: an achievable goal or an illusion? Am J Respir Crit Care Med. 2012;186:i-iii. Editorial.
14. Centers for Disease Control and Prevention (CDC). Transmission of Mycobacterium tuberculosis in a High School and School-Based Supervision of an Isoniazid-Rifapentine Regimen for Preventing Tuberculosis - Colorado, 2011-2012. MMWR Morb Mortal Wkly Rep. 2013 Oct 4;62(39):805-9. PubMed PMID: 24080593.450a1. PubMed PMID:26720627.
15. Reves R, Schluger NW. Update in tuberculosis and nontuberculous mycobacterial infections 2013. Am J Respir Crit Care Med. 2014;189:894-8. doi:10.1164/rccm.201402-0210UP. PubMed PMID: 24735031. Editorial.
16. Reves RR. In reply. Int J Tuberc Lung Dis. 2015;19:495. PubMed PMID: 25860012. Letter to the editor.
17. Walter ND, Reves R, Davis JL. Blood transcriptional signatures for tuberculosis diagnosis: a glass half-empty perspective. Lancet Respir Med. 2016;4:e28. PubMed PMID: 27304799. Letter to the editor.
18. Reves R, Daley CL. Screening for Latent Tuberculosis Infection: A Key Step Toward Achieving Tuberculosis Elimination in the United States. JAMA Intern Med. 2016;176:1439-1440. PubMed PMID: 27599130. Editorial.
19. Reves R, Benjamin R. The cost of the failure to eliminate tuberculosis in the United States. Int J Tuberc Lung Dis 2017;21:120. Letter to the editor.

20. Belknap R, Reves R. Is it time to rethink the role of AFB smears? *Int J Tuberc Lung Dis* 2017;21:720. Editorial.
21. Belknap R, Reves R. In reply: We and our patients must demand better TB diagnostics. *Int J Tuberc Lung Dis*. 2017 Dec 1;21:1316. PubMed PMID: 29297457.
22. Haas MK, Reves R. Strong Community-Public Health Partnerships May Help Us Move Closer to Tuberculosis Elimination. *Am J Public Health*. 2019 Jul;109(7):958-959. PubMed PMID: 31166724.